Seasonal influenza vaccination is the most important way of preventing seasonal influenza virus infections and potentially severe complications, including death. Seasonal influenza vaccination reduces the likelihood of becoming ill with influenza or transmitting influenza to others.•Seasonal influenza vaccines do not contain the 2009 H1N1 strain and are not expected to provide significant cross-protection against pandemic (H1N1) 2009 influenza.² Influenza A (H1N1) 2009 monovalent vaccines to prevent the 2009 H1N1 virus have been licensed; initial doses of licensed vaccine are expected to be available by mid-October 2009.•Two types of seasonal influenza vaccine are licensed by the Food and Drug Administration (FDA) for use in the United States: trivalent influenza vaccine (TIV) and live, attenuated influenza vaccine (LAIV).•TIV is injected into the muscle of the upper arm or thigh. It can be used for people 6 months of age or older, including those with chronic medical conditions, pregnant ...
Background: Following the emergence of the 2009 pandemic influenza A(H1N1) virus, monovalent influenza vaccines were developed and marketed in Europe. Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project, we estimated the pandemic influenza vaccines effectiveness (PIVE) using sentinel general practitioners (GP) influenza surveillance networks in seven European countries.. Methods: We conducted a multicentre case-control study between November 2009 and March 2010. Using systematic sampling, GPs swabbed patients presenting with influenza-like illness (ILI European Union case definition) within eight days of symptom onset and collected their vaccination history and a list of potential confounders (e.g. age group, chronic diseases and related hospitalisations, seasonal influenza vaccination). Cases were ILI patients with laboratory-confirmed pandemic influenza. Controls were ILI patients testing negative for influenza. Vaccination was defined as having received one dose ...
The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called universal influenza vaccines, and to explore a path towards the standardisation of such assays. To address this critical topic, a workshop on Immunoassay standardisation for universal influenza vaccines was co-organised in June 2015 by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health / National Institute of Allergy and Infectious Diseases, USA. The workshop agenda encompassed a wide range of immunoassays that can be used to assess immune responses to broadly reactive influenza vaccines, from classical serological assays to assays measuring cell mediated immunity. The workshop audience agreed that it was not possible to establish one universal immunoassay for universal influenza vaccine(s) because the approaches towards these vaccines ...
Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with ...
Current influenza vaccines are trivalent or quadrivalent inactivated split or subunit vaccines administered intramuscularly, or live attenuated influenza vaccines (LAIV) adapted to replicate at temperatures below body temperature and administered intranasally. Both vaccines are considered safe and efficient, but due to differences in specific properties may complement each other to ensure reliable vaccine coverage. By now, licensed LAIV are produced in embryonated chicken eggs. In the near future influenza vaccines for human use will also be available from adherent MDCK or Vero cell cultures, but a scalable suspension process may facilitate production and supply with vaccines. We evaluated the production of cold-adapted human influenza virus strains in the duck suspension cell line AGE1.CR.pIX using a chemically-defined medium. One cold-adapted A (H1N1) and one cold-adapted B virus strain was tested, as well as the reference strain A/PR/8/34 (H1N1). It is shown that a medium exchange is not required for
In June 2006, the Advisory Committee on Immunization Practices (ACIP) expanded its 2004 recommendation for routine influenza vaccination of children aged 6--23 months to include children aged 24--59 months. The 2006 ACIP recommendations also reemphasized that previously unvaccinated children aged ,9 years should receive 2 doses of influenza vaccine administered at least 1 month apart to be fully vaccinated (1). In 2007, using data from six immunization information system (IIS)* sentinel sites, CDC conducted the first assessment of influenza vaccination coverage among children aged 6--59 months during the 2006--07 influenza season. The findings demonstrated that, at all six sites, ,30% of children aged 6--23 months and ,20% of children aged 24--59 months were fully vaccinated. Vaccination coverage data from national and state surveys for an influenza season generally are not available until the next influenza season. Rapid assessment of influenza vaccination coverage can help direct activities of ...
Results: The overall sample consisted of 4,011 people. The influenza vaccination coverage rate in Germany increased from 22.3% in 2002/2003 to 25.1% in 2003/2004. This increase is not significant. The most frequent reasons for being vaccinated given by vaccinees were: influenza considered to be a serious illness, which people wanted to avoid (90.1%), having received advice from the family doctor or nurse to be vaccinated (71.3%), and not wanting to infect family and friends (70.4%). Reasons for not being vaccinated mentioned by people who have never been vaccinated were: thinking about it, however, not being vaccinated in the end (47.7%), not expecting to catch influenza (43.6%), and not having received a recommendation from the family doctor to be vaccinated (36.6%). Options encouraging influenza vaccination are: recommendation by the family doctor or nurse (66.6%), more available information on the vaccine regarding efficacy and tolerance (54.2%), and more information available about the ...
Recommendations for seasonal influenza vaccination are standard in most developed countries. Many rapidly developing countries have recently begun to adopt recommendations for high-risk target groups, such as the elderly. Population-based surveys to determine use, rather than purchases, of seasonal …
To estimate effectiveness of seasonal trivalent and monovalent influenza vaccines against pandemic influenza A (H1N1) 2009 virus, we conducted a test-negative case-control study in Victoria, Australia, in 2010. Patients seen for influenza-like illness by general practitioners in a sentinel surveillance network during 2010 were tested for influenza; vaccination status was recorded. Case-patients had positive PCRs for pandemic (H1N1) 2009 virus, and controls had negative influenza test results. Of 319 eligible patients, test results for 139 (44%) were pandemic (H1N1) 2009 virus positive. Adjusted effectiveness of seasonal vaccine against pandemic (H1N1) 2009 virus was 79% (95% confidence interval 33%-93%); effectiveness of monovalent vaccine was 47% and not statistically significant. Vaccine effectiveness was higher among adults. Despite some limitations, this study indicates that the first seasonal trivalent influenza vaccine to include the pandemic (H1N1) 2009 virus strain provided significant
INTRODUCTION: Seasonal (inactivated) influenza vaccination is recommended for all individuals aged 65+ and in individuals under 65 who are at an increased risk of complications of influenza infection, for example, people with asthma. Live attenuated influenza vaccine (LAIV) was recommended for children as they are thought to be responsible for much of the transmission of influenza to the populations at risk of serious complications from influenza. A phased roll-out of the LAIV pilot programme began in 2013/2014. There is limited evidence for vaccine effectiveness (VE) in the populations targeted for influenza vaccination. The aim of this study is to examine the safety and effectiveness of the live attenuated seasonal influenza vaccine programme in children and the inactivated seasonal influenza vaccination programme among different age and at-risk groups of people. METHODS AND ANALYSIS: Test negative and cohort study designs will be used to estimate VE. A primary care database covering 1.25 ...
Routine influenza vaccination of health-care personnel (HCP) every influenza season can reduce influenza-related illness and its potentially serious consequences among HCP and their patients (1-5). To protect HCP and their patients, the Advisory Committee on Immunization Practices (ACIP) recommends that all HCP be vaccinated against influenza during each influenza season (5). To estimate influenza vaccination coverage among HCP during the 2012-13 season, CDC conducted an opt-in Internet panel survey of 1,944 self-selected HCP during April 1-16, 2013. This report summarizes the results of that survey, which found that, overall, 72.0% of HCP reported having had an influenza vaccination for the 2012-13 season, an increase from 66.9% vaccination coverage during the 2011-12 season (6). By occupation type, coverage was 92.3% among physicians, 89.1% among pharmacists, 88.5% among nurse practitioners/physician assistants, and 84.8% among nurses. By occupational setting, vaccination coverage was highest ...
The report firstly introduced Influenza Vaccine (Split Virion),Inactivated basic information included Influenza Vaccine (Split Virion),Inactivated definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Influenza Vaccine (Split Virion),Inactivated industry policy and plan, Influenza Vaccine (Split Virion),Inactivated product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers Influenza Vaccine (Split Virion),Inactivated capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Influenza Vaccine (Split Virion),Inactivated products customers application capacity market position company contact information etc company related information, then collect all these manufacturers data and listed ...
5 Countries of Europe Collectively Control more than 80 percent in the Europe Influenza Vaccine Market. Influenza virus is mostly activated in the winter season every year in the European region. Vaccination is the best way to prevent from Influenza virus. It is anticipated that Influenza vaccine market is near to US$ 1 Billion due to a large target population, strong public healthcare infrastructure, high per capita healthcare spending and influenza vaccination program in European countries. Our research report title Europe Influenza Vaccine Market, Vaccinated Population (23 Countries Market Data) By (Child & Adult) & Forecast cover the following points:. • Influenza vaccinated population (Children and Adult vaccinated population). • Influenza vaccinated market (Children and Adult vaccinated market). • Influenza Vaccine Covered (Vaxigrip/Fluzone, Fluarix/ Flulaval, FluMist/Fluenz, Afluria/Fluvax and Fluvirin/Flucelvax, Anflu). • 23 Countries Covered (Netherlands, Denmark, Estonia, ...
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.. Get Free 10% Customization in this Report. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022. Download Full Report: ...
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.. Get Free 10% Customization in this Report. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022. Download Full Report: ...
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.. Get Free 10% Customization in this Report. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022. Download Full Report: ...
The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of MF59-adjuvanted subunit seasonal influenza vaccine with respect to immunogenicity in subjects aged 65 years and older. The active comparator non-adjuvanted seasonal influenza vaccine is approved for use in this age group in the United States and will be used to provide a comparative assessment for immunogenicity and safety ...
To determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on humoral antibody responses, measured by hemagglutinin inhibition assay (HAI), to each of three strains included in the seasonal non-adjuvanted trivalent influenza vaccine In this study we will use the following definitions to assess the humoral immune response to TIV: HAI titers ,1:10 = seronegative; HAI titers ≥1:10 = seropositive; HAI titers ≥1:40 = sero-protective; sero-response rate (primary outcome measure) will be defined as a titer of ≥1:40 in an individual with baseline titers of ,1:10, or ,4-fold increase of HAI titers if baseline titers were ≥1:10. Hemagglutination inhibition assays will be performed on serum as per recommended methods. Sera will be titrated against antigens from the influenza vaccine strains included in the 2013 seasonal TIV ...
Background Influenza vaccines are reviewed each year, and often changed, in an effort to maintain their effectiveness against drifted influenza viruses. There is however no regular review of influenza vaccine effectiveness during, or at the end of, Australian influenza seasons. It is possible to use a case control method to estimate vaccine effectiveness from surveillance data when all patients in a surveillance system are tested for influenza and their vaccination status is known. Methodology/Principal Findings Influenza-like illness (ILI) surveillance is conducted during the influenza season in sentinel general practices scattered throughout Victoria, Australia. Over five seasons 2003-7, data on age, sex and vaccination status were collected and nose and throat swabs were offered to patients presenting within three days of the onset of their symptoms. Swabs were tested using a reverse transcriptase polymerase chain reaction (RT-PCR) test. Those positive for influenza were sent to the World Health
Latest industry research report on Influenza Vaccines Market. Influenza is a type of seasonal or pandemic condition causing fever, coryza, cough, headache, and malaise. The severity of influenza symptoms varies across age groups and type of influenza. According to the World Health Organization (WHO), approximately, 3 to 5 million people are prone to seasonal epidemics, annually.. The growing number of ageing population and an increase in the frequency of seasonal influenza outbreak supplement the demand for influenza vaccines across the healthcare industry. Intellectual property rights are providing security to the patent holders, thereby, increases their market share. However, the upcoming patent expirations for top influenza vaccines and the growing popularity of influenza drugs as over the counter (OTC) products would provide an opportunity for generic manufacturers.. Get Free Sample Report Of Influenza Vaccines Market @ ...
Vaccination against influenza is considered the most important public health intervention to prevent unnecessary hospitalizations and premature deaths related to influenza in the elderly, though there are significant inequities among global influenza vaccine resources, capacities, and policies. The objective of this study was to assess the social determinants of health preventing adults ≥65 years old from accessing and accepting seasonal influenza vaccination. A systematic search was performed in January 2011 using MEDLINE, ISI - Web of Science, PsycINFO, and CINAHL (1980-2011). Reference lists of articles were also examined. Selection criteria included qualitative and quantitative studies written in English that examined social determinants of and barriers against seasonal influenza vaccination among adults≥65 years. Two authors performed the quality assessment and data extraction. Thematic analysis was the main approach for joint synthesis, using identification and juxtaposition of themes
We used a mathematical model with two circulating influenza strains to evaluate the effect of modified pH1N1 infection risk following receipt of seasonal influenza vaccine on optimal seasonal vaccination strategies in the Canadian population. Our projections suggest that, in the presence of the best currently available information on the epidemiology of pH1N1 in Canada, the decisions by several jurisdictional health authorities to restrict or delay the use of seasonal vaccines until after the likely peak of the autumn pandemic wave represents a reasonable choice under uncertainty. Specifically, in the presence of low levels of co-circulating seasonal influenza strains, even a relatively small enhancement of risk associated with vaccination has a negative impact on total influenza-attributable mortality if the entire population is immunized at usual vaccination coverage. At higher levels of co-circulating seasonal influenza, the impact of this enhanced risk is less marked, as seasonal vaccine has ...
While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case-control study to estimate IVE against hospitalis …
Hannah Blake. pharmaphorum. A new seasonal influenza vaccine has been approved by the Food and Drug Administration for use in the United States. Developed by Protein Sciences Corp, Flubok is the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.. Unlike current flu vaccines, Flublok does not use the influenza virus or eggs in its production. Flubloks novel manufacturing technology allows for production of large quantities of the influenza virus protein, hemagglutinin (HA) - the active ingredient in all inactivated influenza vaccines that is essential for entry of the virus into cells in the body. The majority of antibodies that prevent influenza virus infection are directed against HA.. While the technology is new to flu vaccine production, it has already been used to make vaccines to prevent other infectious diseases. These ...
Health care providers should not use live attenuated influenza vaccine (LAIV) in the upcoming 2016-17 season due to poor effectiveness, a Centers for Disease Control and Prevention (CDC) committee said Wednesday.. Academy leaders say they support the interim recommendation by the CDCs Advisory Committee on Immunization Practices (ACIP).. We agree with ACIPs decision today to recommend health care providers and parents use only the inactivated vaccine for this influenza season, said AAP President Benard Dreyer, M.D., FAAP.. The AAP recommends children ages 6 months and older be immunized against influenza every year. Previously, the CDC and AAP had recommended either form of flu vaccine - the inactivated influenza vaccine (IIV) that is given by injection and is approved for all patients older than 6 months, or LAIV which is given by intranasal spray and is approved for healthy patients ages 2 through 49 years.. However, new data presented to the ACIP showed that currently only IIV provides ...
Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5-30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and
Studies Fail To Demonstrate Safety Or Effectiveness Of Influenza Vaccine In Children And Adults. An independent analysis by the internationally renowned Cochrane Collaboration of worldwide influenza vaccine studies, published in the British Medical Journal on Oct. 28, concluded there is little scientific proof that inactivated influenza vaccine is safe and effective for children and adults. Citing the Cochrane Collaboration finding as well as methodological flaws in a child influenza vaccine study published Oct. 25 in the Journal of the American Medical Association (JAMA), the National Vaccine Information Center is calling on the Centers for Disease Control (CDC) to stop recommending annual flu shots for all infants and children until methodologically sound studies are conducted.. There is a big gap between policies promoting annual influenza vaccinations for most children and adults and supporting scientific evidence, said epidemiologist Tom Jefferson, Cochrane Vaccines Field, Rome, Italy, ...
TY - JOUR. T1 - Seasonal influenza vaccination rates in the HIV outpatient study-United States, 1999-2013. AU - Durham, Marcus D.. AU - Buchacz, Kate. AU - Armon, Carl. AU - Patel, Pragna. AU - Wood, Kathy. AU - Brooks, John T.. AU - Hays, Harlen. AU - Wood, Kathleen C.. AU - Hankerson, Darlene. AU - Debes, Rachel. AU - Subramanian, Thilakavathy. AU - Dean, Bonnie. AU - Palella, Frank J.. AU - Chmiel, Joan S.. AU - Jahangir, Saira. AU - Flaherty, Conor Daniel. AU - Dixon-Evans, Jerian Denise. AU - Lichtenstein, Kenneth A.. AU - Stewart, Cheryl. AU - Hammer, John. AU - Greenberg, Kenneth S.. AU - Widick, Barbara. AU - Franklin, Rosa. AU - Yangco, Bienvenido G.. AU - Chagaris, Kalliope. AU - Ward, Doug. AU - Thomas, Troy. AU - Avery, Patricia. AU - Fuhrer, Jack. AU - Ording-Bauer, Linda. AU - Kelly, Rita. AU - Esteves, Jane. AU - Tedaldi, Ellen M.. AU - Christian, Ramona A.. AU - Ruley, Faye. AU - Beadle, Dania. AU - Graham, Princess. AU - Novak, Richard M.. AU - Wendrow, Andrea. AU - Smith, ...
Influenza, however, is unique among respiratory viral pathogens in that another effective intervention to prevent transmission exists: vaccination. Annual influenza vaccination has been available in the United States since 1945 and has been recommended for persons at high risk of influenza complications since 1960. Unlike many pathogens, the predominant circulating influenza strains vary from year to year, affecting the intensity and severity of the influenza season as well as vaccine effectiveness. According to a recent systematic review and meta-analysis of influenza vaccine protection, there was 59% effectiveness of the trivalent influenza vaccine in adults aged 18 to 65 years and a higher effectiveness (83%) of the live-attenuated vaccine (LAIV) in children.3Although not at levels of other vaccines, influenza vaccination provides some protection and may prevent complications due to influenza such as pneumonia, hospitalizations, and death. Recent studies in children have demonstrated that the ...
According to recent research published in the Pediatrics journal, patients should not use the nasal spray flu vaccine in 2016. This statement supports previous recommendations from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC),. These recommendations are based on research which reveals that the nasal spray flu vaccine, also known as the live attenuated influenza vaccine (LAIV), offered low protection against certain types of influenza between 2013 and 2016 and does not offer the required efficacy.. The data gathered from the United States Influenza Vaccine Effectiveness Network showed that LAIV offered only 3% protection against any flu virus during the 2015-2016 flu season in children aged 2 to 17 years. By comparison, the inactivated influenza vaccine (IIV), the injectable flu vaccine, proved more effective, offering 63 percent protection against any influenza strain.. MedImmunes LAIV, FluMist was also found to offer poor or ...
Live attenuated influenza vaccine (LAIV) offers the promise of inducing a variety of immune responses thereby conferring protection to circulating field strains. LAIVs are based on cold adapted and temperature sensitive phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of seasonal influenza strains. Two types of MDV lineages have been described, the Ann Arbor lineages and the A/Leningrad/17 and B/USSR/60 lineages. Here the safety and immunogenicity of a Madin Darby Canine Kidney - cell culture based, intranasal LAW derived from A/Leningrad/17 and B/USSR, was evaluated in healthy influenza non-naive volunteers 18-50 years of age. In a double-blind, randomized, placebo-controlled design, single escalating doses of 1 x 10(5),1 x 10(6), or 1 x 10(7) tissue culture infectious dose 50% (TCID50) of vaccine containing each of the three influenza virus re-assortants recommended by the World Health Organization for the 2008-2009 season were administered intranasally. A ...
BACKGROUND: The objective of this study was to assess the predictive effects of socioeconomic factors to explain influenza vaccination coverage rates in 11 European countries. METHODS: Data from national household surveys collected over up to seven consecutive seasons between 2001/2002 and 2007/2008 were analyzed to assess the associations of socioeconomic factors with immunization against influenza. RESULTS: In total, data from 92,101 household contacts representative for the national non-institutionalized population aged above 14 years were analyzed. Influenza vaccination coverage rates in Europe remain suboptimal with little or no progress in the last years. The results of this study indicate that gender, household income, size of household, educational level and population size of living residence may significantly contribute to explain chances of getting immunized against influenza apart from the known risk factors age and chronic illness. The effect of these socioeconomic factors was ...
Observations on Vaccine Production Technologies and Factors Potentially Influencing Pandemic Influenza Vaccine Choices in Developing Countries A discussion paper World Health Organization SoulMiitAtiaR* WestwnhcMc~ � SEA-TRH-006 Distribution: Limited Observations on Vaccine Production Technologies and Factors Potentially Influencing Pandemic Influenza vaccine Choices in Developing Countries A discussion paper World Health Organization Regional Office for South-East Asia �@ World Health Organization 2009 This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named ...
Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary. The level of antibody response made to seasonal influenza vaccines depends on the vaccine preparation, dose, prior antigenic experience, and age or underlying disease conditions of an individual Slideshow 158272 by...
The report aims to provide a critical review of evidence on the barriers and drivers of seasonal influenza vaccination coverage in the EU/EEA. The report focuses on high-risk groups where high coverage of seasonal flu vaccination is most important. The 2009 Council of the European Union Recommendation on seasonal influenza vaccination encourages countries to implement measures that would increase seasonal influenza vaccination uptake to at least 75% for defined older age groups, and, if possible, for other risk groups. In support of this, the ECDC report summarises the evidence on what are the barriers and what are the drivers for seasonal influenza vaccination by each risk group ...
The report aims to provide a critical review of evidence on the barriers and drivers of seasonal influenza vaccination coverage in the EU/EEA. The report focuses on high-risk groups where high coverage of seasonal flu vaccination is most important. The 2009 Council of the European Union Recommendation on seasonal influenza vaccination encourages countries to implement measures that would increase seasonal influenza vaccination uptake to at least 75% for defined older age groups, and, if possible, for other risk groups. In support of this, the ECDC report summarises the evidence on what are the barriers and what are the drivers for seasonal influenza vaccination by each risk group ...
This approval represents a technological advance in the manufacturing of an influenza vaccine, stated Karen Midthun, director of the FDAs Center for Biologics Evaluation and Research. The new technology offers the potential for faster startup of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus.. Unlike current flu vaccines, Flublok does not use the influenza virus or eggs in its production. Flubloks novel manufacturing technology allows for production of large quantities of the influenza virus protein, hemagglutinin - the active ingredient in all inactivated influenza vaccines that is essential for entry of the virus into cells in the body. The majority of antibodies that prevent influenza virus infection are directed against HA. While the technology is new to flu vaccine production, it is used to make vaccines that have been approved by the FDA to prevent other infectious ...
TY - JOUR. T1 - Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant. AU - Fatunmbi, Olufemi O.. AU - Newman, John A.. AU - Sivanandan, V.. AU - Halvorson, David A. PY - 1992. Y1 - 1992. N2 - Trivalent avian influenza (AIV) antigens (H4N8, H5N2 and H7N3), mixed with positively charged, negatively charged and neutral avridine-containing liposomes, and oil-emulsion were subcutaneously administered to 6-week-old turkeys. Charged liposomal avridine adjuvant, either positive or negative, produced a better antibody response than uncharged liposomal avridine or oil-emulsion adjuvants when used in a trivalent avian influenza vaccine. The antibody response to the different antigens was generally greater to the positively charged adjuvanted vaccine compared with the negatively or neutral charged or oil-emulsion adjuvanted vaccines and these differences were significant (p , 0.05) with the three antigens. The results suggest that ...
Posts about Seasonal Influenza Vaccine Uptake in Frontline Healthcare workers HCWs Survey 2013‐2014 written by Dementia and Elderly Care News
Lancet Infectious Diseases Jan 2018 Volume 18 Number 1 p1-122 e1-e32 http://www.thelancet.com/journals/laninf/issue/current Personal View Urgent challenges in implementing live attenuated influenza vaccine Anika Singanayagam, Maria Zambon, Ajit Lalvani, Wendy Barclay Summary Conflicting reports have emerged about the effectiveness of the live attenuated influenza vaccine. The live attenuated influenza vaccine appears to protect particularly poorly against…
Looking for online definition of influenza vaccine in the Medical Dictionary? influenza vaccine explanation free. What is influenza vaccine? Meaning of influenza vaccine medical term. What does influenza vaccine mean?
This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated
PubMed journal article Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute otitis media in childre were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
No safety signals were observed with the administration of quadrivalent live attenuated influenza vaccine, according to a large population study.
Vol 5: Live Attenuated Influenza Vaccine Enhances Colonization of Streptococcus pneumoniae and Staphylococcus aureus in Mice.. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Background Since 2004, the uptake of seasonal influenza vaccines in Latin America and the Caribbean has markedly increased. However, vaccine effectiveness (VE) is not routinely measured in the region. We assessed the feasibility of using routine surveillance data collected by sentinel hospitals to estimate influenza VE during 2012 against laboratory-confirmed influenza hospitalizations in Costa-Rica, El Salvador, Honduras and Panama. We explored the completeness of variables needed for VE estimation. Methods We conducted the pilot case-control study at 23 severe acute respiratory infections (SARI) surveillance hospitals. Participant inclusion criteria included children 6 months-11 years and adults ≥60 years targeted for vaccination and hospitalized for SARI during January-December 2012. We abstracted information needed to estimate target group specific VE (i.e., date of illness onset and specimen collection, preexisting medical conditions, 2012 and 2011 vaccination status and date, and ...
Annual recommendations on influenza seasonal vaccination include community pharmacists, who have low vaccination coverage. The aim of this study was to investigate the relationship between influenza vaccination in community pharmacists and their knowledge of and attitudes to vaccination. An online cross-sectional survey of community pharmacists in Catalonia, Spain, was conducted between September and November 2014. Sociodemographic, professional and clinical variables, the history of influenza vaccination and knowledge of and attitudes to influenza and seasonal influenza vaccination were collected. The survey response rate was 7.33% (506 out of 6906); responses from 463 community pharmacists were included in the final analyses. Analyses were performed using multivariable logistic regression models and stepwise backward selection method for variable selection. The influenza vaccination coverage in season 2013-2014 was 25.1%. There was an association between vaccination and correct knowledge of the virus
[177 Pages Report] Check for Discount on Global Avian Influenza Vaccines Consumption 2016 Market Research Report report by QYResearch Group. The Global Avian Influenza Vaccines Consumption 2016 Market Research Report...
Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada Academic Article ...
Two phylogenetic lineages of influenza B virus coexist and circulate in the human population (B/Yamagata and B/Victoria) but only one B-strain is included in each seasonal vaccine. Mismatch regularly occurs between the recommended and circulating B-strain. Inclusion of both lineages in vaccines may offer better protection against influenza. This study (NCT00714285) assessed the immunogenicity and safety of two candidate quadrivalent influenza vaccines (QIV) containing two A- and two B-strains (one from each lineage) in adults (18-60 years). Subjects were randomized and stratified by age to receive either QIV (non-adjuvanted or low-dose adjuvanted [LD QIV-AS]) or trivalent influenza vaccine (TIV, non-adjuvanted or low-dose adjuvanted [LD TIV-AS]), N = 105 in all treatment groups. The study evaluated the statistical non-inferiority of the immunological response elicited by QIV and LD QIV-AS versus TIV and LD TIV-AS and the statistical superiority of the response elicited by the quadrivalent vaccines
PubMed journal article Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza seaso were found in PRIME PubMed. Download Prime PubMed App to iPhone, iPad, or Android
Follow the six-step administration guide for FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) nasal spray seasonal flu vaccine.
To the Editor: Adult vaccination rates are low (1), and workplaces are a useful location for increasing vaccination (2). In 2008, only 41% of US workers 50-64 years of age reported vaccination against influenza virus (3). Workplace vaccination is common and increases with employer size (4). Among adults, the workplace is the most common site for influenza vaccination for persons 18-49 years of age and second most common for persons 50-64 years (2). Offering vaccination in the workplace increases vaccination coverage (5).. Consistent with guidelines and economic incentives, employers have focused workplace vaccination on seasonal influenza (4), but the workplace has also been a key site for vaccination against influenza A pandemic (H1N1) 2009 and could be a site for other adult vaccinations. The most recent guidelines from the Advisory Committee on Immunization Practices recommend annual influenza vaccination of all adults (6). In most years, the seasonal influenza vaccine and predominant ...
EDITORIAL. The scramble for influenza vaccine in 2010. In 2009 South Africa, like the rest of the world, experienced the swine flu pandemic caused by influenza A (H1N1) 2009 virus (H1N1). The influenza epidemic curve for South Africa during 2009 testified to the introduction of the virus, as it superseded the influenza A H3N2 strain (H3N2) as the predominant circulating virus at the end of the season.1 Predicting patterns of influenza is difficult, and although most influenza cases in South Africa in 2010 may also be due to H1N1, it is uncertain to what degree H3N2 and influenza B will play their parts. Mercifully, H1N1 in 2009 caused mild influenza-like illness (ILI) in most infected persons; with 12 640 laboratory-confirmed cases (a portion of the true number), only 93 laboratory-confirmed H1N1-associated deaths occurred.2,3. When a new pandemic influenza virus is introduced into a susceptible population, previously healthy people are at risk of severe disease, as are high-risk groups with ...
EDITORIAL. The scramble for influenza vaccine in 2010. In 2009 South Africa, like the rest of the world, experienced the swine flu pandemic caused by influenza A (H1N1) 2009 virus (H1N1). The influenza epidemic curve for South Africa during 2009 testified to the introduction of the virus, as it superseded the influenza A H3N2 strain (H3N2) as the predominant circulating virus at the end of the season.1 Predicting patterns of influenza is difficult, and although most influenza cases in South Africa in 2010 may also be due to H1N1, it is uncertain to what degree H3N2 and influenza B will play their parts. Mercifully, H1N1 in 2009 caused mild influenza-like illness (ILI) in most infected persons; with 12 640 laboratory-confirmed cases (a portion of the true number), only 93 laboratory-confirmed H1N1-associated deaths occurred.2,3. When a new pandemic influenza virus is introduced into a susceptible population, previously healthy people are at risk of severe disease, as are high-risk groups with ...
INTRODUCTION Determining the optimal time to vaccinate is important for influenza vaccination programmes. Here, we assessed the temporal characteristics of influenza epidemics in the Northern and Southern hemispheres and in the tropics, and discuss their implications for vaccination programmes. METHODS This was a retrospective analysis of surveillance data between 2000 and 2014 from the Global Influenza B Study database. The seasonal peak of influenza was defined as the week with the most reported cases (overall, A, and B) in the season. The duration of seasonal activity was assessed using the maximum proportion of influenza cases during three consecutive months and the minimum number of months with 80% of cases in the season. We also assessed whether co-circulation of A and B virus types affected the duration of influenza epidemics. RESULTS 212 influenza seasons and 571,907 cases were included from 30 countries. In tropical countries, the seasonal influenza activity lasted longer and the peaks ...
JJ KAPOJOS1, A BRITTON1, T WHITTINGTON1, SP McDONALD1. 1Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia Aim: To analyse the effectiveness of an active influenza vaccination policy in hemodialysis (HD) patients in a large metropolitan dialysis service.. Background: In response to a high frequency of hospitalisations, in 2016 a program of actively offering vaccination to satellite HD patients was undertaken. Influenza B increased in 2015; influenza vaccination was changed to quadrivalent in 2016.. Methods: Numbers of patients admitted with a positive influenza nucleic acid testing (NAT) were tabulated from 2012 to 2016. Positive cases in HD patients were further characterised for hospital length of stay, age, gender, race, potential contributors and mortality.. Results: Included were 550 patients managed across 15 units. Vaccination uptake improved from 67.3% in 2015 to 77.8% in 2016. However, the proportion of all hospital ...
Description of Invention:. National Institutes of Health (NIH) inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing, cross-protective antibodies-one directed to the highly conserved HA stem and a second proximal to the conserved receptor binding site (RBS) of the viral HA-providing a new platform for universal and seasonal influenza. In addition, HA-ferritin nanoparticles can be easily produced from simple expression vectors and without the production of infectious virus in eggs, and will facilitate influenza preparedness in the face of emerging epidemics.. This technology exploits ferritin, a ubiquitous iron storage protein, that self-assembles into spherical nanoparticles and could serve as a ...
This trial will compare the immunogenicity and safety of a quadrivalent influenza vaccine, and two trivalent influenza vaccines, in adult and elderly subjects.
United States Seasonal Influenza Vaccine Market Report 2017 is a market research report available at US $3800 for a Single User PDF License from RnR Market Research Reports Library.
Downloadable! We evaluate the results of a field experiment designed to measure the effect of prompts to form implementation intentions on realized behavioral outcomes. The outcome of interest is influenza vaccination receipt at free on-site clinics offered by a large firm to its employees. All employees eligible for study participation received reminder mailings that listed the times and locations of the relevant vaccination clinics. Mailings to employees randomly assigned to the treatment conditions additionally included a prompt to write down either (i) the date the employee planned to be vaccinated or (ii) the date and time the employee planned to be vaccinated. Vaccination rates increased when these implementation intentions prompts were included in the mailing. The vaccination rate among control condition employees was 33.1%. Employees who received the prompt to write down just a date had a vaccination rate 1.5 percentage points higher than the control group, a difference that is not statistically
The influenza A and B viruses that routinely spread in people are responsible for seasonal flu epidemics each year. Over the course of a flu season (which typically occurs between October and May), different types of influenza are passed from person-to-person, causing illness. Usually, vaccination with the seasonal influenza vaccine provides some protection against the strains of flu that are circulating at the time. CDC recommends that everyone 6 months and older get a seasonal flu vaccine each year.. A novel influenza virus is an influenza A virus with a subtype that is different from the flu viruses that usually spread in people (H3N2 and H1N1). Some examples include H7N9, and H5N1. Occasionally, strains of influenza that normally affect birds, pigs, and other animals can infect humans. When flu viruses that normally affect pigs (swine flu viruses) cause infections in humans, these viruses are called variant influenza viruses. One example of a variant flu virus is H3N2v.. Sometimes, human ...
National Influenza Vaccination Week is December 1-7. Its Not Too Late to Vaccinate!. Richland County, OH - The Centers for Disease Control and Prevention (CDC) established National Influenza Vaccination Week (NIVW) in 2005 to highlight the importance of continuing flu vaccination through the holiday season and beyond. Previous flu vaccination coverage data have shown that few people get vaccinated against influenza after the end of November. The CDC and its partners choose December for NIVW to remind people that even though the holiday season has begun, it is not too late to get a flu vaccine. Heres why:. ...
Demicheli, V., T. Jefferson, L.A. Al-Ansary, E. Ferroni, A. Rivetti, and C. Di Pietrantonj. Vaccines for Preventing Influenza in Healthy Adults. Cochrane Database Syst Rev 13.3 March 2014: CD001269. Grohskopf, L.A., L.Z. Sokolow, K.R. Broder, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2018-19 Influenza Season. MMWR 67.3 Aug. 24, 2018: 1-20. Lambert, L., and Fauci, A. Influenza Vaccines for the Future. New Eng. J. Med. 361.21 (2010): 2036-2044. Monto, A.S., Ohmit, S.E., Petrie, J.G., Johnson, E., Truscon, R., Teich, E., Rotthoff, J., Boulton, M., Victor, J.C. Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines. N Engl J Med 361 Sept. 24, 2009: 1260. Nguyen, H. Influenza. Medscape.com. Aug. 22, 2016. ,http://emedicine.medscape.com/article/219557-overview,. Perez-Padilla, R., de la Rosa-Zamboni, D., Ponce de Leon, S.P., Hernandez, M., Quinones-Falconi, F., ...
Results and conclusion Knowing that the vaccine is effective (mhRR 2.22; 95% CI 1.93 to 2.54), being willing to prevent influenza transmission (mhRR 2.31; 95% CI 1.97 to 2.70), believing that influenza is highly contagious (RR 2.25; 95% CI 1.66 to 3.05), believing that influenza prevention is important (mhRR 3.63; 95% CI 2.87 to 4.59) and having a family that is usually vaccinated (RR 2.32; 95% CI 1.64 to 3.28) were statistically significantly associated with a twofold higher vaccine uptake. We therefore recommend targeting these predictors when developing new influenza vaccination implementation strategies for hospital HCWs. ...
That staff at Waikato Hospital have been bullied into accepting influenza vaccinations, according to the NZ Herald is absolutely unacceptable in a democracy and is an assault on workers human rights.. Katherine Smith, spokeswoman for No Forced Vaccines says that she is appalled to learn that one staff member has been sacked because he or she did not comply with the new hospital policy regarding influenza vaccination. [1]. Influenza vaccination carries serious risks, including the risk of developing Guillain Barre syndrome, a disorder of the nervous system which can involve varying degrees of paralysis and can be fatal in some cases, Mrs Smith continues.. Its not surprising that many health professionals refuse influenza vaccinations, presumably because they do not want to put their health at risk. [2]. She rejects the hospitals claim that unvaccinated staff pose a risk to patients.. People who are not vaccinated do not necessarily contract the flu if they are exposed to it, she ...
Current licensed influenza vaccines induce hemagglutination inhibition (HAI) antibodies that do not cross-react with influenza strains that have undergone genetic drift. There is an urgent unmet need for more broadly protective seasonal influenza vaccines with greater breadth, enhanced potency, and durability of HAI responses. It is currently impossible to predict which antigenic variants may evolve, and therefore, novel vaccine candidates are needed that will elicit immunity to potential variants. Recently, we designed a new technology termed COBRA as a universal/more broadly reactive vaccine approach for both emerging/pandemic influenza viruses and currently circulating influenza subtypes. We have published a series of studies demonstrating the effectiveness of the COBRA HA antigens for H5N1 (11-13).. This method was applied to address the diversity within the H1N1 HA and yields a vaccine that elicits increased breadth of antibody response within the H1 influenza subtype. The method uses ...
Summary Parenteral immunization of BALB/c mice at 3 months of age with inactivated influenza virus vaccine elicited a haemagglutinin (HA)-specific serum IgG antibody response. The magnitude of this response declined with advancing age at the time of vaccination. By contrast, HA-specific IgA and IgG antibody levels observed in lung lavage fluids of mice immunized at 1 and 2 years of age were comparable to those of 5 month old mice when inactivated influenza virus vaccine was administered intragastrically. The secretory immune response was not fully developed in the first 3 weeks of life. However, the HA-specific IgA and IgG responses to oral vaccination in sera were reduced in 1 or 2 year old mice when compared to 5 month old mice. These data demonstrated the preservation of the virus-specific secretory IgA response in the pulmonary fluids of aged mice after oral vaccination with inactivated influenza virus vaccine. An age-dependent difference of systemic and mucosal immunity was evident in orally
Influenza immunisation for healthcare workers is encouraged to protect their often vulnerable patients but also due to a perceived higher risk for influenza. We aimed to compare the risk of influenza infection in healthcare workers in acute hospital care with that in non-healthcare workers over the same season. We conducted a prospective, multicentre cohort study during the 2006/07 influenza season in Berlin, Germany. Recruited participants gave serum samples before and after the season, and completed questionnaires to determine their relevant exposures and possible confounding factors. The main outcome measure was serologically confirmed influenza infection (SCII), defined as a fourfold or greater rise in haemagglutination inhibition antibody titres to a circulating strain of influenza (with post-season titre at least 1:40). Weekly mobile phone text messages were used to prompt participants to report respiratory illnesses during the influenza season. A logistic regression model was used to assess the
As indicated in the 2004 Association for Professionals in Infection Control and Prevention (APIC) position paper, the importance of improving influenza immunization rates among HCWs is a very necessary component of ensuring patient safety and protection (p. 123). In addition, immunization provides an extra level of personal protection for the HCW. Transmission of the influenza virus can spread rapidly from HCWs to patients and patients to HCWs, creating a vicious cycle. An institutional influenza outbreak can exacerbate staff shortages in clinical areas, not only by creating additional patient risk factors but also by further stressing hospital resources and increasing patient morbidity and mortality.2. One neonatal intensive care unit (NICU) reported an outbreak of influenza among 19 neonates with one outbreak related death that occurred. The source case was suspected to be an employee, although that could not be confirmed. The facility reported a 15 percent influenza immunization compliance ...
The holiday season has already started, and so has flu season. Thats why the CDC has designated the week of December 4 - 10, 2016, as National Influenza Vaccination Week. Once November ends and the holiday season starts, people tend to forget about getting their flu shot. In fact, research from past flu seasons has shown that very few people get a flu shot after the end of November. And not only that, but last flu season, only 40% of those recommended to get a flu shot actually got one by the end of November. This means almost 60% of the U.S. population remained unprotected from the flu after flu season had already started. Even though flu season has begun, its not too late to get your flu shot. So long as the flu virus is still circulating, you can get sick with the flu, which is why it is so important to protect yourself with the flu vaccine. And not only will you be protecting yourself, but those around you as well. Young children, the elderly, pregnant women and people with certain chronic ...
Background: Influenza and pneumococcal vaccination are recommended in patients with chronic obstructive pulmonary disease (COPD). A recent study from Tayside found a reduced risk of all cause mortality with vaccination in COPD patients.. Objectives: We used The Health Improvement Network (THIN) database to test this hypothesis in a different data source.. Methods: We searched the THIN database for patients with COPD. Vaccination status against pneumococcus and their annual influenza vaccination status were determined. Mortality rates were calculated in the periods December-March, April-November. Relative risks for the effect of vaccination on all cause mortality were estimated by Poisson regression, adjusting for age, sex, year and serious co-morbidities.. Results: We found 177,120 patients with COPD, mean age of 65 years, with an average of 6.8 years follow up between 1988 and 2006. Vaccination rates against influenza rose from ,30% prior to 1995 to ,70% in 2005 among patients aged 60 years or ...
The researchers also compared vaccination rates to effectiveness of the shot against the virus during the prior flu season.. Generally, they noted a downward trend in vaccination rates in recent years, and that none of the three variables -- severity of the current influenza season, severity of prior season or vaccine effectiveness -- had a significant effect on these numbers.. For example, the 2010-2011 flu season, which the CDC deemed high severity, vaccination rates for most age groups of children hovered around 60 percent or less, with the exception of infants between 6 and 23 months old.. The CDC considered the flu season immediately prior, 2009-10, to be of moderate severity, and vaccine effectiveness for both the 2009-10 and 2010-2011 seasons was around 60 percent for all pediatric age groups except teens.. Fortunately, in the just released CDC influenza vaccination data, the downward trend in vaccination was reversed this past season, Stockwell said. However, it still remains ...
We found that immunization against influenza during pregnancy had a substantial effect on mean birth weight and the proportion of infants who were small for gestational age but only during the period of increased circulating influenza virus in the community.. Our data suggest that the prevention of infection with seasonal influenza in pregnant women by immunization can influence fetal growth. It has been reported that infection with pandemic influenza virus has substantial adverse effects in pregnant women and fetuses;14-18 however, there are limited similar data from epidemic seasonal influenza illness.3. The chronology of the specific effect of influenza vaccine on mean birth weight that we describe is distinct from the previously described general seasonality of birth weights in Bangladesh. Studies from Bangladesh have shown a seasonal pattern of reduction in the mean birth weights of full-term infants and an increase in the number of preterm infants in the season called monga, September to ...
Suspension for Intramuscular Injection. …. 5 WARNINGS AND PRECAUTIONS. 5.1 Guillain-Barré Syndrome. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks.. 5.2 Altered Immunocompetence. If Influenza A (H1N1) 2009 Monovalent Vaccine is administered to immunocompromised persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained.. 5.3 Preventing and Managing Allergic Reactions. Prior to administration of any dose of Influenza A (H1N1) 2009 Monovalent Vaccine, the healthcare provider should review the patients prior immunization history for possible adverse events, to determine the existence of any contraindication to immunization with Influenza A (H1N1) 2009 Monovalent Vaccine and to allow an assessment of benefits and risks. Appropriate medical treatment and ...
We studied the influenza vaccination of HCWs and the social network defined by conversations around a vaccination campaign. A major finding is that similarity in vaccination behavior did not play a significant role in the probability of naming another HCW in our hospital. Links were more likely when individuals shared a professional category, sex, age, or department. In addition, some characteristics influenced participants citing more HCWs (being younger, having a position of responsibility, some professional categories) and others which increased the likelihood of being cited as a link (being vaccinated).. The lack of homophily according to vaccination behavior, also described for influenza vaccination in a friendship network of medical students [28], contrasts with other studies of advice networks in parental vaccination decisions [24-26] and in a contact network of influenza vaccination in high school students [27], where homophily by vaccination status was observed. The differences between ...
OFFICE OF THE VICE CHANCELLOR - STUDENT AFFAIRS OFFICE OF STUDENT HEALTH SERVICES October 9, 2020 University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093 ALL STUDENTS AT UC SAN DIEGO Important Information Regarding Flu Vaccination for 2020-21 Academic Year for Students UC San Diego is committed to the health and safety of all. The most important measure to prevent flu infection is an annual flu vaccination and is even more important during a pandemic. Similar to the steps we take to reduce COVID-19 infection such as wearing a face covering, physical distancing, and good hand hygiene, getting an annual flu vaccination helps stop the spread in the community in addition to protecting yourself and your campus community. The University of California has issued a systemwide executive order requiring all members of the UC community to receive an influenza immunization before November 1, 2020 if they plan to be on campus during the flu season, which is anticipated to extend through the
Wood noted that this achievement is particularly impressive given this years periodic shortages of seasonal influenza vaccine and the complex messages for seniors resulting from the introduction of a second influenza vaccine for H1N1. We recognize that this achievement would not have been possible without the combined efforts of all facets of Alaskas health care community, including our public health centers, tribal health corporations, physicians offices and clinics, pharmacies, community health centers and other partnering groups that worked so hard this year to provide influenza vaccine for our seniors ...
Influenza vaccination of elderly individuals is recommended worldwide as people aged 65 and older are at a higher risk of complications, hospitalisations and deaths from influenza. This review looked at evidence from experimental and non-experimental studies carried out over 40 years of influenza vaccination. We included 75 studies. These were grouped first according to study design and then the setting (community or long-term care facilities). The results are mostly based on non-experimental (observational) studies, which are at greater risk of bias, as not many good quality trials were available. Trivalent inactivated vaccines are the most commonly used influenza vaccines. Due to the poor quality of the available evidence, any conclusions regarding the effects of influenza vaccines for people aged 65 years or older cannot be drawn. The public health safety profile of the vaccines appears to be acceptable.. ...
The Washington County Health Department is having its second flu vaccination clinic of the season Oct. 26.With flu vaccinations widely available through local pharmacies, including ones at grocery
NaturalHealth365) Makers of the flu vaccine claim receiving it decreases the risk of getting sick due to the triggering of antibody development in the body. However, a Chinese study reveals quite the opposite.. Researchers in Hong Kong have found that in addition to actually increasing the risk of flu, receiving the flu vaccine also raises the risk of getting a respiratory infection by 5.5 times. The study was published in the journal Clinical Infectious Diseases.. Stringent double-blind study shows disturbing side effects of flu vaccine. While research on the side effects of the flu vaccine have been lacking in the U.S., Chinese researchers have been more active about looking into the possible side effects of flu shot. This recent study conducted in Hong Kong looked at vaccinated versus unvaccinated subjects and how they fared health-wise.. In the study, the seasonal trivalent flu vaccine was tested for side effects of flu shot. What makes this effort particularly noteworthy is the fact that it ...